The concept that erythropoiesis is under humoral control was first advanced at the beginning of the twentieth century,' but proof came only in 1950 when Reissman used two animals with a common blood circulation to show that when one animal was made hypoxic erythrocytosis occurred in both.2 Around the same time Erslev showed that infusion of plasma from anaemic rabbits produced reticulocytosis in recipients. 3 The part played by the kidney in producing this humoral mediator of erythropoiesi s-erythropoietin-was first suggested by Jacobson et al,4 but filual proof came only recently with the finding within renal cells of mRNA for erythropoietin. 5 The past decade has seen enormous changes in our knowledge of erythropoietin-firstly, with its purification and the determination ofits primary amino acid sequence6 and later with the isolation of the erythropoietin gene and its expression in mammalian cell lines. 7 Erythropoietin is a glycoprotein made up of 165 amino acids and four complex carbohydrate chains that are rich in sialic acid and account for 40% ofthe total molecular weight of 34000 daltons.6 The glycosylation is not essential for the function of erythropoietin but contributes to preventing rapid hepatic clearance of the desialated form. 9 The main production site in postfetal life is the kidney, with erythropoietin being formed in peritubular cells in the cortex and outer medulla.'0 The origin of the cells producing erythropoietin remains unclear: they may be endothelial or of macrophage origin." In fetuses the liver is the main source of erythropoietin and continues to play a very minor part in adults."
In simple terms erythropoietin is secreted by the kidney in response to decreased oxygen supply and it stimulates erythropoiesis. A classic negative feedback loop is set up to maintain oxygen supply at a constant level. This concept requires an oxygen sensor that responds to venous oxygen pressure'2 and which also seems to depend on tubular reabsorption of sodium,'3 thereby allowing some independence of renal production of erythropoietin from renal blood flow. The precise mechanism whereby hypoxia stimulates production of erythropoietin is uncertain.
Erythropoietin stimulates erythropoiesis by controlling the proliferation and maturation of erythroid progenitors: two have been described -burst forming unit erythroid and colony forming unit erythroid.' 1 The early progenitor, burst forming unit erythroid, is stimulated by erythropoietin at high concentration and by other haemopoietic growth factors including interleukin-3 and granulocyte-monocyte colony stimulating factor, and the main amplification of erythroid progenitors seems to occur at this level.'5 The late progenitor, colony forming unit erythroid, is responsive only to erythropoietin and not to other growth factors. The effects of erythropoietin on colony forming unit erythroid are mainly those of differentiation and maturation. '5 There seem to be from 300 to 3000 receptors per cell,'6 but their nature is not yet clarified-that is, whether both high and low affinity receptors are present or only a single high affinity class.'7 18 The physiological changes in serum erythropoietin activity and its relation to tissue oxygen delivery are well known and have been cogently reviewed recently. " In patients with renal failure serum erythropoietin concentrations are consistently lower than in patients with anaemia of comparable degree that is not due to renal failure.20 Anephric patients have even lower erythropoietin concentrations and are correspondingly more severely anaemic.2' The anaemia seen in patients with rheumatoid arthritis may also be associated with lower than expected erythropoietin concentrations for the degree of anaemia,2 though others have disputed this. 23 Recombinant human erythropoietin has been used successfully in several clinical settings. Most of the published data are from trials in patients in end stage renal failure and are consistent.2426 Good results are obtained both in terms of correction of anaemia and of improvement in wellbeing and energy. These responses are similar to those after renal transplantation. 26 The correction of anaemia by recombinant human erythropoietin allows patients in end stage renal failure to become independent of blood transfusion: potential annual savings of 250 000 units of blood in the United States have been suggested." Treatment with recombinant human erythropoietin causes an increase in demand for iron to cope with the sustained increase in erythropoiesis: a failure in the expected rise in haemoglobin concentration should raise the possibility of iron deficient erythropoiesis, which may be corrected simply with iron supplements. The main side effects are worsening of control of blood pressure and an increase in thrombotic complications.2425 Preliminary data suggest that the rate of rise of the packed cell volume is an important factor in poor control of blood pressure and that the dose of recombinant human erythropoietin should be adjusted to prevent too rapid a rise. '6 Some patients with rheumatoid arthritis have been treated, with slight improvement in anaemia but no improvement in clinical symptoms. 27 Other conditions in which recombinant BMJ VOLUME 300 10 MARCH 1990
Erythropoietin: an old friend revisited How this hormone stimulates blood production is now better understood human erythropoietin is being used include the anaemia of prematurity, myelodysplastic syndromes, and anaemia associated with HIV infection. It has also been used to increase the number ofunits of blood harvested for autologous transfusion. People differ widely in their emotional responses to physical illness. Persistent emotional disturbance is more common in those with a history of psychiatric illness' or with inadequate social supports.2 Whether or not a patient becomes depressed or anxious is only weakly associated, if at all, with the severity of the illness or of the physical symptoms.' 3-6 What seems to matter most are the sufferer's cognitions: attitudes to and thoughts and beliefs about the illness.
Emotional disturbance is particularly associated with dysfunctional cognitions-that is, beliefs that do not serve an adaptive purpose and are given exaggerated emphasis or may even be false. For example, a man who believed that his myocardial infarct had resulted from his straining to pass urine was anxious and unable to return to his previous life because he felt unable to close the door whenever he was using the lavatory. Terminal illness does not necessarily prevent a person from settling his or her affairs or from getting enjoyment as before through being with family and friends. Yet some patients who are terminally ill develop the dysfunctional belief that all happiness will henceforth totally elude them. If this belief results in their withdrawing from social intercourse it becomes self fulfilling. Emotional disturbance is not inevitably linked with dysfunctional cognitions, however, and similarly not all abnormal beliefs are dysfunctional. For example, a man who was undergoing haemodialysis long term had worked out a plan to commit suicide if his circumstances oLc-unie intolerable. Despite continuing suicidal thoughts he coped adequately with his illness. He became severely depressed when he discovered that he could not bring himself to end his life. Undue optimism may help some patients with cancer,7 and excessive denial may also be adaptive in some circumstances."' Such clinical observations are well supported by evidence from research. For example, the degree of pain and disability in arthritis are more closely associated with cognitive variables than with the duration or severity of the illness."1'S Patients with low back pain who are also depressed have more distorted perceptions of the impact of their back pain than their non-depressed peers. 16 Patients with a variety of illnesses who believe that their symptoms might become uncontrollable are more likely to be depressed or anxious, regardless of their physical state.2''7 18 In a recent study of outpatients in a dermatology clinic Wessely and Lewis found that psychiatric morbidity was independent of the site, extent, or duration of the skin disease but related to attitudes towards appearance and to the behavioural impact of the skin disorder. '9 Dysfunctional or not, cognitions are usually unspoken, beyond normal awareness, and taken as axiomatic. Dysfunctional beliefs about illness commonly reflect lay or idiosyncratic theories of disease, which may be difficult for doctors to recognise or expect and so need to be elicited actively. Learning to identify and to modify dysfunctional cognitions are core elements of cognitive therapy.20 This is well established as being effective for depression2' and is being applied to a growing range of problems.2226 Its efficacy has been shown in managing chronic pain2728 and in reducing the psychiatric morbidity associated with cancer293' as well as the disability caused by asthma32 and chronic obstructive airways disease.33
